Increased brain MAO-A levels in major depressive disorder

Primary Psychiatry

Volumn 14, Issue 12, 2007, Pages 32-34

  Robinson, Donald S ^a  

^a Worldwide Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; MONOAMINE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN;

BRAIN METABOLISM; ENZYME LOCALIZATION; HUMAN; MAJOR DEPRESSION; MONOAMINE METABOLISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SEROTONIN METABOLISM; SHORT SURVEY;

EID: 37349110305     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63(11):1209-16.
2. Zhu MY, Klimek V, Dilley GE, et al. Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry. 1999;46(9):1275-86.
3. Boldrini M, Underwood MD, Mann JJ, Arango V. More tryptophan hydroxylase in the brainstem dorsal raphe nucleus in depressed suicides. Brain Res. 2005;1041(1):19-28.
4. Bonkale WL, Murdock S, Janosky JE, Austin MC. Normal levels of tryptophan hydroxylase immunoreactivity in the dorsal raphe of depressed suicide victims. J Neurochem. 2004;88(4):958-64.
5. Mann JJ, Huang YY, Underwood MD, et al. A serotonin transporter gene promoter polymorphism (%-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry. 2000;57(8):729-738.
6. Meyer JH, Kruger S, Wilson AA, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12(18):4121-4125.
7. Austin MC, Whitehead RE, Edgar CL, et al. Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects commiting suicide. Neuroscience. 2002;114(3):807-815.
8. Neumeister A, Willeit M, Praschak-Rieder N, et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med. 2001;31(8):1467-1473.
9. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology. 1998;51(2 suppl 2):2-9.
10. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res. 2003;37(5):357-373.
11. Mann JJ. Role of serotonin system in the pathogenesis of major depression and suicide. Neuropsychopharmacology. 1999;21(2 suppl):99-105.
12. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry. 2004;61(12):1271-1279.
13. Bergstrom M, Westerberg G, Langstrom B. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol. 1997;24(4):287-293.
14. Bergstrom M, Westerberg G, Kihlberg T, Langstrom B. Synthesis of some 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. Nucl Med Biol. 1997;24(5):381-388.
15. Ginovart N, Meyer JH, Boovariwala A, et al. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab. 2005;26(3):330-344.